Connecting oncology professionals with relevant clinical trials

Selected clinical trial

Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity

Sponsor: Heinrich-Heine-Universitaet Duesseldorf

Phase: 1

Disease: Recurrent glioblastoma

EU trial number: 2026-525397-19-00

Population: Adults aged 18–75 years with IDH-wildtype WHO grade 4 glioblastoma at first recurrence, eligible for re-resection after standard chemoradiation and at least three temozolomide cycles, able to produce autologous tumor lysate-based DC vaccine.

Register Investigator Interest

Interested in offering this trial to suitable patients?